Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 10,808 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed No phase listed Observational

The Impact of Community-based Wellness Programs on The Triple Aim

NCT02938130
View directory record Official record
Conditions
Spina Bifida, Cerebral Palsy, Spinal Cord Injury, Traumatic Brain Injury
Interventions
Wellness Programs
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
7 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 5:04 AM EDT
Not listed No phase listed Observational

Cure Cystinosis International Registry

NCT01327807
View directory record Official record
Conditions
Cystinosis, Nephropathic Cystinosis, Renal Fanconi Syndrome
Interventions
Not listed
Lead sponsor
Cystinosis Research Foundation
Other
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

NCT00195936
View directory record Official record
Conditions
Hypophosphatemic Rickets, X-Linked Dominant
Interventions
Cinacalcet
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre-SunBeam TEWL AUC

NCT04226092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GPSkin Barrier Pro, Aquaflux AF200
Device
Lead sponsor
Northwestern University
Other
Eligibility
0 Years to 3 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Denver, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 28, 2026, 5:04 AM EDT
Completed No phase listed Observational

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina

NCT03253211
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
4,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 28, 2026, 5:04 AM EDT
Completed No phase listed Observational

Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers

NCT01138371
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
LDL Apheresis
Procedure
Lead sponsor
Emory University
Other
Eligibility
3 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 28, 2026, 5:04 AM EDT
Completed No phase listed Observational

Fetal Growth Evaluation by Three-Dimensional Ultrasound

NCT00340171
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
1,919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
2
States / cities
Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 28, 2026, 5:04 AM EDT
Terminated Not applicable Interventional Results available

Pediatric REPlAcement of the PulmonaRy ValvE in Tetralogy of Fallot -

NCT03634072
View directory record Official record
Conditions
Tetralogy of Fallot
Interventions
PVR
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Not applicable Interventional

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

NCT00187057
View directory record Official record
Conditions
Ataxia-Telangiectasia
Interventions
vinblastine, vincristine, prednisone, daunorubicin, doxorubicin, methotrexate, cyclophosphamide, L-asparaginase, etoposide, cytarabine, mercaptopurine, dexamethasone, procarbazine, chemotherapy, intrathecal chemotherapy, steroid therapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 10 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Oct 28, 2026, 5:04 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

NCT01007357
View directory record Official record
Conditions
Diffuse and Focal Abnormalities of the Liver and Pancreas
Interventions
Body MR imaging
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Not applicable Interventional

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

NCT00002095
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the AMICUS RBCx System in Sickle Cell Patients

NCT02372877
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Amicus Red Cell Exchange in SCD patients
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
6 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Detroit, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT00008177
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions
iodine I 131 monoclonal antibody BC8, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 28, 2026, 5:04 AM EDT
Terminated Not applicable Interventional Results available

Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure

NCT00833365
View directory record Official record
Conditions
Patent Ductus Arteriosus, Prematurity
Interventions
Ibuprofen
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 96 Hours
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 28, 2026, 5:04 AM EDT
Completed No phase listed Observational

Energy Balance and Weight Gain With Ivacaftor Treatment

NCT02141464
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 28, 2026, 5:04 AM EDT
Recruiting No phase listed Observational

OCT in Fuchs' Dystrophy

NCT04258787
View directory record Official record
Conditions
Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 28, 2026, 5:04 AM EDT
Recruiting Phase 1 Interventional

ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

NCT05682144
View directory record Official record
Conditions
Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
Interventions
Autologous Plasmablasts (B cells)
Biological
Lead sponsor
Immusoft of CA, Inc.
Industry
Eligibility
10 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2044
U.S. locations
2
States / cities
Oakland, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 28, 2026, 5:04 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

NCT00681863
View directory record Official record
Conditions
Tourette Syndrome
Interventions
pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID, pramipexole 0.25 mg BID, pramipexole 0.0625 mg BID
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Phase 2 Interventional

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

NCT04040816
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
SAP-001
Drug
Lead sponsor
Shanton Pharma Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Anaheim, California • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Phase 1 Interventional Results available

Mild, Moderate and Severe Renal Impairment Study

NCT02219516
View directory record Official record
Conditions
Gout
Interventions
RDEA3170
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 28, 2026, 5:04 AM EDT
Completed Phase 2Phase 3 Interventional

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

NCT03920228
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
PTX-022, Placebo
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 28, 2026, 5:04 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

NCT06545136
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
FLT201
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 28, 2026, 5:04 AM EDT
No Longer Available No phase listed Expanded access

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

NCT00870636
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab (Avastin)
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
30 Weeks and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 28, 2026, 5:04 AM EDT
No Longer Available No phase listed Expanded access

Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)

NCT02084121
View directory record Official record
Conditions
Metachromatic Leukodystrophy
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 28, 2026, 5:04 AM EDT